Stryker Corporation $SYK Shares Sold by Premier Fund Managers Ltd

Premier Fund Managers Ltd trimmed its stake in shares of Stryker Corporation (NYSE:SYK) by 7.5% during the 4th quarter, Holdings Channel reports. The fund owned 24,746 shares of the medical technology company’s stock after selling 2,020 shares during the quarter. Premier Fund Managers Ltd’s holdings in Stryker were worth $8,765,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in SYK. Vanguard Group Inc. grew its position in shares of Stryker by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after acquiring an additional 133,892 shares during the period. Alliancebernstein L.P. lifted its holdings in Stryker by 13.3% during the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after purchasing an additional 741,542 shares in the last quarter. Legal & General Group Plc lifted its stake in Stryker by 4.4% in the 3rd quarter. Legal & General Group Plc now owns 2,303,290 shares of the medical technology company’s stock valued at $851,457,000 after buying an additional 96,662 shares in the last quarter. Corient Private Wealth LLC lifted its position in shares of Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after acquiring an additional 1,146,998 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Stryker by 4.5% during the third quarter. Invesco Ltd. now owns 1,864,918 shares of the medical technology company’s stock worth $689,404,000 after buying an additional 80,536 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SYK has been the subject of several recent research reports. Weiss Ratings cut Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday. William Blair reiterated an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Needham & Company LLC dropped their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday, May 1st. Barclays cut their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research report on Monday. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $465.00 target price on shares of Stryker in a report on Wednesday, March 4th. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $395.48.

Stryker Price Performance

NYSE:SYK opened at $292.13 on Thursday. Stryker Corporation has a 52 week low of $289.91 and a 52 week high of $404.87. The stock’s fifty day moving average is $342.12 and its two-hundred day moving average is $355.73. The company has a market capitalization of $111.88 billion, a P/E ratio of 33.81, a P/E/G ratio of 1.86 and a beta of 0.80. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts expect that Stryker Corporation will post 14.97 EPS for the current year.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.